Author
Listed:
- Vladimir A Parfenov
- Volodymyr A Golyk
- Eduard I Matsnev
- Svetlana V Morozova
- Oleg A Melnikov
- Ludmila M Antonenko
- Elena E Sigaleva
- Maksym I Situkho
- Olena I Asaulenko
- Vasyl I Popovych
- Maxim V Zamergrad
Abstract
Background: Vestibular vertigo is associated with substantially reduced quality of life. Betahistine is effective in improving vertigo-associated symptoms, with longer treatment periods leading to greater improvements; however, it is not known whether these effects persist after treatment cessation. Methods: VIRTUOSO was a prospective, multinational, non-comparative, post-marketing observational programme investigating the effectiveness of betahistine (48 mg/day) and the course of vertigo after the discontinuation of treatment. Patients with vestibular vertigo who were prescribed 48 mg/day betahistine were enrolled in Russia and Ukraine. Treatment duration was up to 2 months, and patients were followed up for 2 months after discontinuation of betahistine. Efficacy endpoints included clinical response (assessed by change in vertigo severity), monthly attack frequency, and physician and patient grading of overall clinical response and improvement of vertigo-associated symptoms. Results: Overall, 309 patients were enrolled and 305 completed the study. Clinical response was rated as good, very good or excellent in 74.1% of patients at end of treatment, with vertigo severity significantly decreased from baseline (p
Suggested Citation
Vladimir A Parfenov & Volodymyr A Golyk & Eduard I Matsnev & Svetlana V Morozova & Oleg A Melnikov & Ludmila M Antonenko & Elena E Sigaleva & Maksym I Situkho & Olena I Asaulenko & Vasyl I Popovych & , 2017.
"Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study,"
PLOS ONE, Public Library of Science, vol. 12(3), pages 1-11, March.
Handle:
RePEc:plo:pone00:0174114
DOI: 10.1371/journal.pone.0174114
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0174114. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.